The present study was carried out to develop mouth dissolving tablets of Repaglinide with a rationale of providing better patient compliance, will serve to provide effective mode of treatment to elderly, impaired and noncooperative patient suffering from diabetes. The Repaglinide-βcyclodextrin complex was prepared in order to increase the solubility of drug. The inclusion efficiency of different ratios of Repaglinide-β-cyclodextrin complex was calculated, that shows the inclusion efficiency of 1:1 molar ratio complex is highest. The mouth dissolving tablets of Repaglinide (RCT1 to RCT5) were prepared by direct compression method using super disintegrants, for optimization of the diluents. The value of pre-compression of blends and postcompression tablets exhibited satisfactorily results. The formulation RCT3 complied with all the physical parameters such as hardness, friability and disintegration time, and taken for further studies. Nine different formulations (RCT6 to RCT14) were prepared by using various concentration of super disintegrant namely Crosscarmellose sodium, Crosspovidone and Sodium Starch Glycolate. Among all formulations studied, formulation RCT9 having crospovidone as disintegrant showed 56.5% drug release in 5 min. Therefore crospovidone is considered best superdisintegrant among Sodium starch glycolate and Crosscarmellose sodium.
Mouth dissolving tablets offering advantages over liquid and traditional dosage forms as it provides the convenience of a tablet formulation, while also allowing the ease of swallowing provided by a liquid formulation. Mouth dissolving tablets allow the luxury of much more accurate dosing than the primary alternative, oral liquids.
A major claim of the some mouth dissolving tablets is increased bioavailability compared to traditional tablets. Because of dispersion in saliva while still in the oral cavity, there can be pre-gastric absorption from some formulations in those cases where the drug dissolves quickly. Buccal, pharyngeal and gastric regions are all areas of absorption of the many formulations 3 . However, other formulations show nearly identical plasma-concentration profiles.
Any pre-gastric absorption avoids first pass metabolism and can be a great advantage in drugs that undergo a great deal of hepatic metabolism. However, if the amount of swallowed drug varies, there is the potential for inconsistent bioavailability. While the claimed increase in bioavailability is disputable, it is clear that the major advantage of these formulations is convenience 1 .
Pharmaceutical marketing is another reason for the increase in available Mouth dissolving products. As a drug entity nears the end of its patent life, it is common for pharmaceutical manufacturers to develop a given drug entity in a new and improved dosage form. A new dosage form allows a manufacturer to extend market exclusivity, while offering its patient population a more convenient dosage form or dosing regimen. In this regard, Mouth dissolving tablet formulations are similar to many sustained release formulations that are now commonly available. An extension of market exclusivity, which can be provided by a mouth dissolving dosage form, leads to increased revenue, while also targeting underserved and under treated patient populations. Although the cost to manufacture these specialized dosage forms exceeds that of traditional tablets, this additional cost is not being passed on to the consumer. Therefore, cost is generally not an issue when recommending these new dosage forms.
The present invention relates to the development of mouth dissolving tablet of Repaglinide-β-cyclodextrin complex. Repaglinide is an oral hypoglycemic agent especially useful for the treatment of diabetes type II. It induces the rapid onset short lasting insulin release. It acts in an analogous manner by binding to sulfonylurea receptor as well as to other distinct receptors. Repaglinide close the ATP dependant K channel into membrane of β cells which depolarizes the β cells and results in opening of the cell's calcium channel, which in turn induces calcium influx dependent insulin secretion.
Repaglinide has poor aqueous solubility, which is the rate-limiting step for absorption of drug. Many attempts or means have been used to increase water solubility of Repaglinide. Solubility can be increased by forming a complex with cyclodextrin. Cyclodextrin enhances the aqueous solubility of drugs through inclusion complexation which will be used to formulate mouth dissolving tablets. This will not only enhance the bioavailability of the drug but also reduce the onset of action due to fast absorption of drug from GIT as drug will be available as ready to absorption i.e. in solution form from the mouth cavity itself.
Materials and Methods

Materials
Repaglinide gifted from Macleods Pharmaceutical Limited Mumbai, India, was off white, odourless powder.
Methods
Preparation and characterization of Repaglinide-β
Cyclodextrin complex
Preparation of physical mixtures and the solid inclusion complex
For physical mixtures, Repaglinide and β-cyclodextrin were weighed accurately at 1:1, 2:1 and 3:1 molar ratios mixed thoroughly by trituration in a mortar and sieved through 0.25 mm sieve. All physical mixtures were stored in dessicator until further evaluation. The inclusion complex of Repaglinide with βcyclodextrin was prepared at 1:1, 2:1 and 3:1 molar ratios by wetting the physical mixture in a mortar with a minimum volume of ethanol and water (1:1 v/v) mixture and kneading thoroughly with a pestle to obtain a paste, which was then dried under vacuum at room temperature, sieved through 0.25 mm sieve and stored in a dessicator until further evaluation.
Inclusion efficiency
The kneaded complex and its physical mixtures (25 mg) were placed in 25-mL volumetric flasks. Methanol (10 ml) was added, mixed thoroughly and sonicated for 30 min. The volume was made up to the mark with methanol. The solution was suitably diluted with the same solvent and spectrophotometrically assayed for drug content at 243.0 nm 4 .
Dissolution studies
Dissolution studies were performed in phosphate buffer (pH 6.8, 900 mL) at 37±0.2°C, using USP XXIII apparatus (Electrolab, India) with a paddle rotating at 50 rpm. Solid products, each containing 50 mg of drug, were subjected to dissolution. At fixed time intervals, samples were withdrawn, filtered (Whatmann filter paper no. 41) and spectrophotometrically assayed for drug content at 243.0 nm. Mouth dissolving tablets were prepared by direct compression method using super disintegrants. Microcrystalline cellulose and lactose used as diluents. The complex equivalent to 1.5 mg of drug was taken and then mixed with directly compressible diluent and superdisintegrants in a container. Magnesium stearate and talc were mixed and blended with the initial mixture followed by compression of the blend. Compression was performed using 10 mm round, flat and plain single punch machine (Table 3 ).
Preparation of mouth dissolving tablets containing a complex of Repaglinide with β-Cyclodextrin
Pre-compression evaluation of powder blend
Bulk density
Bulk density was determined by placing the powders blend in a measuring cylinder and the total volume is noted. The weight of powder bed was determined by using digital weighing balance. Bulk density was calculated using the following formula:
Bulk Density = Weight of the powder / Volume of the powder 
Tapped density
Compressibility index
The compressibility was calculated using the equation:
Percent compressibility or carr's index = [(tap -bulk)/tap] × 100
Where bulk is the bulk density (g/mL) and tap is the tap density (g/mL) 4-6
Evaluation of mouth dissolving tablets
Friability test
Friability of tablets was determined using Roche friabilator (Electolab, Mumbai). This device subjects the tablets to the combined effect of abrasions and shock in a plastic chamber revolving at 25 rpm and dropping the tablets at a height of six inches in each revolution. Preweighed sample of tablets was placed in the friabilator and were subjected to 100 revolutions. Tablets were dedusted using a soft muslin cloth and reweighed. The friability is given by the formula:
Where, Wo is the weight of the tablets before the test and W is the weight of the tablet after the test.
Hardness
Hardness or tablet crushing strength (Fc) (the force required to break a tablet in a diametric compression was measured using Monsanto hardness tester.
Drug content
Four tablets were powdered and the blend equivalent to 6 mg of Repaglinide was weighed and dissolved in suitable quantity of phosphate buffer of pH 6.8. The solution was filtered, suitably diluted and the drug content was analyzed spectrophotometrically at 243 nm. Each sample was analyzed in triplicate.
Measurement of liquid uptake
A glass petridish was partially filled with water and a tablet was placed on the surface of a band of filter paper supported on a glass slide. The uptake of water occurred from the lower surface of the tablet. The time required for water to reach the center of the upper surface of the tablet was noted as wetting time.
Disintegration Time
The disintegration time (DT) was measured using a modified disintegration method, which is reported by Gohel et al. (2007) for mouth dissolving tablets. For this purpose, a petri dish (10-cm diameter) was filled with 10 ml of water. The tablet was carefully put in the center of the petridish and the time for the tablet to disintegrate completely into fine particles was noted 5 .
In-vitro dissolution study
The and in-vitro dissolution study by using standard procedures [7] [8] [9] .
Results and Discussions
Preparation and characterization of Repaglinide-β Cyclodextrin complex
The Repaglinide-β-cyclodextrin complex was prepared in order to increase the solubility of drug. The complex and physical mixture of Repaglinide and βcyclodextrin were prepared in different ratios of drug and βcyclodextrin (1:1, 2:1 and 3:1) and inclusion efficiency of different ratios was calculated, that shows the inclusion efficiency of 1:1 molar ratio complex is highest (Table 1) .
Dissolution study of drug, physical mixture and Repaglinide -βcyclodextrin complex have shown in table 2 that showed complex is more soluble than drug and physical mixture.
Preparation of mouth dissolving tablets containing a complex of
Repaglinide with β-Cyclodextrin
The pharmacokinetic data revealed that Repaglinide is low permeable drug and less water soluble. Hence the basic aim of the formulation was to release the drug from the formulation instantly in water soluble form.
The values of pre-compression parameters evaluated, were within prescribed limits and indicated a good free flowing property ( Table   4 ). The data obtained from post-compression parameters such as weight variation, hardness, friability, wetting time, drug content and in vitro disintegration for prepared tablets were satisfactorily ( Table 5 & Table 6 ).
The results of pre-compression and post-compression indicate that product complied with the physical parameters. The formulation RCT3 exhibited good flow properties, less disintegration time (43 sec) and optimum dissolution rate (Table 7) compared to other formulations. Value shown in tables is mean of three determinations Value shown in tables is mean of three determinations complied with all the physical parameters such as hardness, friability and disintegration time. So ratio of lactose and microcrystalline cellulose 3:4 was optimized and taken for further studies.
Formulation of mouth dissolving tablets to assess effect of disintegrants
To point out disintegrants influence on the properties of directly compressible tablets among the various controls carried out throughout the operating procedure. The following parameters such as flow ability of blend, %compressibility of blend, physical properties of tablets were considered to optimize the formulation: Value shown in tables is mean of three determinations Bulk densities of various formulations were varied between 0.46 to 0.52 (gm/cm 3 ). The angle of repose values also varied from 26 to 34 (Table 9 ). Among all the formulation RCT6 and RCT9 exhibited good flow properties.
In all the formulations, the hardness test indicated good mechanical strength, whereas friability is less than 1%, which indicated that the tablets had a good mechanical resistance (Table 10 ). Drug content was found to be high (≥98.11%) and uniform in all the tablets. Value shown in tables is mean of three determinations
The tablets were subjected for evaluation of the in vitro disintegration time (Figure 1 and 2 Thus, tablet disintegration is retarded to some extent with tablets containing Sodium starch glycolate when compared with the . These results suggest that using wicking type of disintegrants like crospovidone can decrease the disintegration time. The dissolution of Repaglinide from the tablets is shown in ( Table 7 and Table 11 ).
The dissolution process of a tablet depends on the wetting followed by disintegration of the tablet. Repaglinide-cyclodextrin  complex  3  3  3  3  3  3  3  3  3   Lactose SD  60  60  60  60  60  60  60  60  60  Starch  40  40  40  40  40  40  40  40  40  Microcrystalline cellulose  80  70  60  80  70  60  80  70  60  Crosscarmellose sodium  10  20 30 Value shown in tables is mean of three determinations Value shown in tables is mean of three determinations The rapid increase in dissolution of Repaglinide with the increase in Crosscarmellose sodium may be attributed to rapid swelling and disintegration 10 of the tablet into apparently primary particles 12 . However, tablets prepared with Sodium starch glycolate disintegrate by rapid uptake of water followed by rapid and enormous swelling into primary particle, but more slowly due to the formation of (Table 10 ).
Selected formulations had disintegration time of less than one minute. Among the combination of superdisintegrants of Microcrystalline cellulose and Crospovidone showed the highest efficiency.
Conclusions
The major problem of Repaglinide is poor bioavailability and its limited aqueous solubility, which may hinder dissolution. Results revealed that it is possible to enhance the dissolution rate and the bioavailability by preparing complex with βcyclodextrin and direct compression technique using different superdisintegrants. The overall results indicate that formulation RCT9, which contains 5%
Crospovidone, was better and that it satisfies all the criteria as a fast dissolving tablet.
